高级检索
    拜明军. 奥曲肽与乌司他丁联合治疗对重症胰腺炎患者血清内毒素和肠粘膜通透性的影响研究[J]. 徐州医科大学学报, 2018, 38(4): 266-268.
    引用本文: 拜明军. 奥曲肽与乌司他丁联合治疗对重症胰腺炎患者血清内毒素和肠粘膜通透性的影响研究[J]. 徐州医科大学学报, 2018, 38(4): 266-268.
    Study on the influence of severe acute pancreatitis patients with serum endotoxin and intestinal permeability and the effects of ulinastatin combined with octreotide treatment[J]. Journal of Xuzhou Medical University, 2018, 38(4): 266-268.
    Citation: Study on the influence of severe acute pancreatitis patients with serum endotoxin and intestinal permeability and the effects of ulinastatin combined with octreotide treatment[J]. Journal of Xuzhou Medical University, 2018, 38(4): 266-268.

    奥曲肽与乌司他丁联合治疗对重症胰腺炎患者血清内毒素和肠粘膜通透性的影响研究

    Study on the influence of severe acute pancreatitis patients with serum endotoxin and intestinal permeability and the effects of ulinastatin combined with octreotide treatment

    • 摘要: 目的:观察分析奥曲肽与乌司他丁联合治疗对重症胰腺炎患者血清内毒素和肠粘膜通透性的影响。方法:随机选取2015年1月~2016年6月于我院就诊的重症胰腺炎患者88例,采用数字随机法均分为观察组(n=44)与对照组(n=44),对照组患者给予奥曲肽治疗,观察组患者给予奥曲肽联合乌司他丁治疗,观察两组患者治疗前后的血清内毒素水平、hs-CRP、肠粘膜通透性。结果:治疗前,两组患者的内毒素、hs-CRP、血浆DAO浓度、L/M比值对比差异不显著,无统计学意义(P>0.05);治疗后,两组患者的内毒素水平、hs-CRP显著低于治疗前(P<0.05),两组患者的血浆DAO浓度显著低于治疗前(P<0.05),L/M比值显著高于治疗前(P<0.05);且观察组患者的内毒素水平、hs-CRP、血浆DAO浓度显著低于对照组(P<0.05),L/M比值显著低于对照组(P<0.05)。结论:采用奥曲肽联合乌司他丁治疗重症胰腺炎患者,能够显著降低患者的血清内毒素水平,且能够帮助恢复患者的肠粘膜屏障功能。

       

      Abstract: Objective: To observe the effect of ulinastatin combined with octreotide and analysis of treatment of severe acute pancreatitis patients with serum endotoxin and intestinal permeability. Methods: 88 patients with severe acute pancreatitis were randomly selected from January 2015 ~2016 year in June in our hospital, were randomly divided into observation group (n=44) and control group (n=44), the control group were treated with octreotide treatment, observation group were treated with octreotide combined with ulinastatin treatment, observation of serum levels of endotoxin, hs-CRP, intestinal mucosal permeability before and after treatment in two groups. Results: before treatment, two groups of patients with hs-CRP, endotoxin, plasma DAO concentration and L/M ratio compared no significant difference, no statistical significance (P>0.05); after treatment, two groups of patients the levels of endotoxin and hs-CRP were significantly lower than those before treatment (P<0.05), the two groups of patients with plasma DAO concentration was significantly lower than that before treatment (P<0.05), the ratio of L/M was significantly higher than that before treatment (P<0.05); and the patients in the observation group the levels of endotoxin, hs-CRP and plasma DAO concentration was significantly lower than the control group (P<0.05), L/M ratio was significantly lower than the control group (P<0.05). Conclusion:The use of octreotide combined with ulinastatin in the treatment of patients with severe acute pancreatitis, can significantly decrease the serum endotoxin level of patients, and can help restore intestinal mucosal barrier function in patients. Key words: Severe acute pancreatitis; octreotide; Ulinastatin; endotoxin; intestinal permeability

       

    /

    返回文章
    返回